| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
ratiopharm, founded in 1974, claims to be Germany's largest generic
manufacturer. This report provides an insight into the company, reviewing its
current business structure and activities.
ratiopharm is headquartered in Ulm, southern Germany. The company claims a
number one position, in terms of generic market share, in Austria, Germany,
Italy, Spain and Switzerland. The company claims top five positions in Canada,
the UK and throughout eastern Europe. ratiopharm employs more than 2,000
people, around 700 of whom are in Germany.
ratiopharm is represented with its own subsidiaries in 18 countries in Europe
and 24 countries world-wide. ratiopharm also owns BioGeneriX, a developer of
generic biological products based in Mannheim. In 2004, the company acquired
Magnafarma, a leading Dutch generic company.
ratiopharm claims to be Germany's largest pharmaceutical company by volume,
selling 166 million packs in 2002. By value, ratiopharm claimed third place in
the German market, with sales of 763 million euros. This was behind only
Pfizer (842 million euros) and Aventis (819 million euros).
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- ratiopharm international subsidiaries
- PRODUCTS
- FINANCIAL RESULTS
- Ratiopharm Sales, 2003-04 (million euro 4)
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- IntelliPharmaCeutics enters generic agreements with ratiopharm
- Neose and BioGeneriX enter new agreement
- ratiopharm ends agreement with Mistral Pharma
- Magnafarma
- BioGeneriX signs agreement with Cangene
- Ribosepharm
- PulmoTec
- Litigation
- Pfizer claims Spanish atorvastatin patent victory.
- CONTACT DETAILS
|
